Clinical Trial Update: Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on anlotinib after lenvatinib in hepatocellular carcinoma patients; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN